Enzeevu (aflibercept-abzv), a biosimilar developed by Sandoz, demonstrated biosimilarity to reference aflibercept (Eylea) in ...
The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...
Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...
In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA ...
Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...
January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...
Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...
January 1 marks the launch of the first biosimilar referencing Stelara (ustekinumab) in the US, ushering in a new class of lower-cost medicines for patients with rheumatic and gastrointestinal ...
Josh Canavan, PharmD, head of pharmacy at RazorMetrics, recommends key educational resources for biosimilars, and emphasizes the extensive research conducted before pharmacy benefit managers (PBMs) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback